NCT03454451: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
|
|
| Completed | 1 | 117 | US, RoW | CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Corvus Pharmaceuticals, Inc. | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 12/22 | 02/23 | | |
